Bruhn Suzanne Louise 4

What Happened
Suzanne Bruhn, a director of Travere Therapeutics (TVTX), received a total of 16,000 shares on 2026-05-19: 4,000 shares and 12,000 derivative shares (both reported as awards) at $0.00 per share. The awards are automatic non-employee director grants under the company’s equity plan; total cash cost to the insider was $0.

Key Details

• Transaction date: 2026-05-19; Filing date: 2026-05-21 (filed within the SEC’s two-business-day Form 4 window).
• Grants: 4,000 shares (A) and 12,000 derivative shares (A), $0.00 per share. Total awarded = 16,000 shares.
• Shares owned after transaction: Not reported in the filing.
• Footnotes: F1 — automatic equity grant under the 2018 Equity Incentive Plan for non-employee directors; F2 — the equity award vests over a one-year period.
• Transaction code: A (award/grant).

Context
These are routine director compensation awards rather than open-market purchases or sales. Derivative awards that vest over time are common for non-employee directors and are primarily a compensation mechanism, not a direct buy or sell signal about the insider’s view of the stock.